{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T09:43:59Z","timestamp":1789379039456,"version":"build-2803163510"},"reference-count":43,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"Suppl. 5","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":2314,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2009,5]]},"abstract":"<jats:sec>\n            <jats:title>Abstract<\/jats:title>\n            <jats:p>Increased treatment options that are more efficacious and safe and new knowledge on the natural history of chronic hepatitis B virus (HBV) infection have expanded the indications for therapy in hepatitis B. The question is no longer \u201cWho should be treated?\u201d but \u201cWhen should treatment be initiated?\u201d Treatment is clearly indicated in patients with life-threatening liver disease (acute liver failure, decompensated cirrhosis, or severe hepatitis flare) and in those with compensated cirrhosis and high levels of serum HBV DNA. For patients with precirrhotic liver disease, treatment indications should be based on clinical, biochemical, or histological evidence of liver disease, such as elevated alanine aminotransferase (ALT) levels, abnormal histology, and high levels of serum HBV DNA. The cutoff for ALT and HBV DNA values are constantly being revised and should be set at a lower level for older patients who may have been infected for a longer period of time. High serum HBV DNA levels persisting for a few decades are associated with increased risk of clinical outcomes, but there is insufficient data to support the initiation of treatment based on high serum HBV DNA alone, particularly in young patients, those with persistently normal ALT levels, and those with a single high HBV DNA level. The decision to initiate treatment at the time of assessment or to defer treatment should take into consideration other factors such as desire to start a family, occupational requirement, family history of hepatocellular carcinoma, access to care and insurance coverage, and commitment to long-term treatment and medication compliance. All patients who are not initiated on treatment should continue to be monitored so treatment can be started if and when the indication arises. (Hepatology 2009;49:S129\u2013S137.)<\/jats:p>\n          <\/jats:sec>","DOI":"10.1002\/hep.22931","type":"journal-article","created":{"date-parts":[[2010,7,5]],"date-time":"2010-07-05T12:32:45Z","timestamp":1278333165000},"page":"S129-S137","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":55,"title":["Indications for therapy in hepatitis B #"],"prefix":"10.1097","volume":"49","author":[{"given":"Bulent","family":"Degertekin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna S. F.","family":"Lok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-16-20241201","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1002\/hep.21513","article-title":"Chronic hepatitis B.","volume":"45","author":"Lok","year":"2007","journal-title":"HEPATOLOGY"},{"key":"R2-16-20241201","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1111\/j.1365-2893.2005.00695.x","article-title":"Safety and efficacy of lamivudine in patients with severe acute or fulminant hepatitis B, a multicenter experience.","volume":"13","author":"Tillmann","year":"2006","journal-title":"J Viral Hepat"},{"key":"R3-16-20241201","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1002\/hep.21486","article-title":"A randomized controlled trial of lamivudine to treat acute hepatitis B.","volume":"45","author":"Kumar","year":"2007","journal-title":"HEPATOLOGY"},{"key":"R4-16-20241201","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1002\/hep.510310130","article-title":"Lamivudine treatment for decompensated cirrhosis resulting from chronic hepatitis B.","volume":"31","author":"Villeneuve","year":"2000","journal-title":"HEPATOLOGY"},{"key":"R5-16-20241201","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1053\/gast.2002.35352","article-title":"Determinants of early mortality in patients with decompensated chronic hepatitis B treated with antiviral therapy.","volume":"123","author":"Fontana","year":"2002","journal-title":"Gastroenterology"},{"key":"R6-16-20241201","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1053\/jhep.2001.26512","article-title":"Lamivudine treatment is beneficial in patients with severely decompensated cirrhosis and actively replicating hepatitis B infection awaiting liver transplantation: a comparative study using a matched, untreated cohort.","volume":"34","author":"Yao","year":"2001","journal-title":"HEPATOLOGY"},{"key":"R7-16-20241201","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/S0168-8278(00)80371-2","article-title":"Lamivudine treatment in patients with severely decompensated cirrhosis due to replicating hepatitis B infection.","volume":"33","author":"Yao","year":"2000","journal-title":"J Hepatol"},{"key":"R8-16-20241201","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1046\/j.1440-1746.2003.02976.x","article-title":"Hepatitis flares and hepatitis B e antigen seroconversion: implication in antihepatitis B virus therapy.","volume":"18","author":"Liaw","year":"2003","journal-title":"J Gastroenterol Hepatol"},{"key":"R9-16-20241201","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1016\/0016-5085(85)90566-9","article-title":"Hepatic decompensation associated with hepatitis B e antigen clearance in chronic type B hepatitis.","volume":"89","author":"Sheen","year":"1985","journal-title":"Gastroenterology"},{"key":"R10-16-20241201","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1046\/j.1365-2893.2002.00385.x","article-title":"The role of lamivudine and predictors of mortality in severe flareup of chronic hepatitis B with jaundice.","volume":"9","author":"Chan","year":"2002","journal-title":"J Viral Hepat"},{"key":"R11-16-20241201","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/S0168-8278(02)00419-1","article-title":"The effect of lamivudine therapy in hepatic decompensation during acute exacerbation of chronic hepatitis B.","volume":"38","author":"Chien","year":"2003","journal-title":"J Hepatol"},{"issue":"Suppl 1","key":"R12-16-20241201","doi-asserted-by":"crossref","first-page":"S99","DOI":"10.1016\/S0168-8278(03)00154-5","article-title":"Interferonalpha for HBeAgpositive chronic hepatitis B.","volume":"39","author":"Craxi","year":"2003","journal-title":"J Hepatol"},{"key":"R13-16-20241201","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1002\/hep.1840400418","article-title":"Clinical outcome of HBeAgnegative chronic hepatitis B in relation to virological response to lamivudine.","volume":"40","author":"Di Marco","year":"2004","journal-title":"HEPATOLOGY"},{"key":"R14-16-20241201","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1002\/hep.20760","article-title":"Outcome of hepatitis B e antigennegative chronic hepatitis B on longterm nucleos(t)ide analog therapy starting with lamivudine.","volume":"42","author":"Papatheodoridis","year":"2005","journal-title":"HEPATOLOGY"},{"key":"R15-16-20241201","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1056\/NEJMoa033364","article-title":"Lamivudine for patients with chronic hepatitis B and advanced liver disease.","volume":"351","author":"Liaw","year":"2004","journal-title":"N Engl J Med"},{"key":"R16-16-20241201","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1001\/jama.295.1.65","article-title":"Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level.","volume":"295","author":"Chen","year":"2006","journal-title":"JAMA"},{"key":"R17-16-20241201","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1053\/j.gastro.2005.11.016","article-title":"Predicting cirrhosis risk based on the level of circulating hepatitis B viral load.","volume":"130","author":"Iloeje","year":"2006","journal-title":"Gastroenterology"},{"key":"R18-16-20241201","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1093\/jnci\/dji043","article-title":"Hepatitis B virus genotype and DNA level and hepatocellular carcinoma: a prospective study in men.","volume":"97","author":"Yu","year":"2005","journal-title":"J Natl Cancer Inst"},{"key":"R19-16-20241201","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1016\/j.cgh.2007.06.015","article-title":"Risk and predictors of mortality associated with chronic hepatitis B infection.","volume":"5","author":"Iloeje","year":"2007","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R20-16-20241201","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1053\/jhep.2002.34294","article-title":"Predictors of HBeAg loss after lamivudine treatment for chronic hepatitis B.","volume":"36","author":"Perrillo","year":"2002","journal-title":"HEPATOLOGY"},{"key":"R21-16-20241201","first-page":"A742","article-title":"Entecavir is effective irrespective of baseline ALT and HBV DNA strata for histological and virological endpoints. Abstract.","volume":"128","author":"Lok","year":"2005","journal-title":"Gastroenterology"},{"key":"R22-16-20241201","doi-asserted-by":"crossref","first-page":"2576","DOI":"10.1056\/NEJMoa066422","article-title":"Telbivudine versus lamivudine in patients with chronic hepatitis B.","volume":"357","author":"Lai","year":"2007","journal-title":"N Engl J Med"},{"key":"R23-16-20241201","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1056\/NEJMoa020681","article-title":"Adefovir dipivoxil for the treatment of hepatitis B e antigenpositive chronic hepatitis B.","volume":"348","author":"Marcellin","year":"2003","journal-title":"N Engl J Med"},{"key":"R24-16-20241201","doi-asserted-by":"crossref","first-page":"2682","DOI":"10.1056\/NEJMoa043470","article-title":"Peginterferon Alfa2a, lamivudine, and the combination for HBeAgpositive chronic hepatitis B.","volume":"352","author":"Lau","year":"2005","journal-title":"N Engl J Med"},{"key":"R25-16-20241201","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1056\/NEJMoa013215","article-title":"Hepatitis B e antigen and the risk of hepatocellular carcinoma.","volume":"347","author":"Yang","year":"2002","journal-title":"N Engl J Med"},{"key":"R26-16-20241201","doi-asserted-by":"crossref","first-page":"2886","DOI":"10.1111\/j.1572-0241.2002.07057.x","article-title":"Effect of hepatitis B and C virus infections on the natural history of compensated cirrhosis: a cohort study of 297 patients.","volume":"97","author":"Fattovich","year":"2002","journal-title":"Am J Gastroenterol"},{"key":"R27-16-20241201","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1002\/jmv.10559","article-title":"Hepatitis B viremia is associated with increased risk of hepatocellular carcinoma in chronic carriers.","volume":"72","author":"Tang","year":"2004","journal-title":"J Med Virol"},{"key":"R28-16-20241201","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1111\/j.1365-2893.2005.00603.x","article-title":"The relationship between HBVDNA levels and cirrhosisrelated complications in Chinese with chronic hepatitis B.","volume":"12","author":"Yuan","year":"2005","journal-title":"J Viral Hepat"},{"key":"R29-16-20241201","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/j.amjmed.2003.12.040","article-title":"Natural history of hepatitis B e antigen to antibody seroconversion in patients with normal serum aminotransferase levels.","volume":"116","author":"Chu","year":"2004","journal-title":"Am J Med"},{"key":"R30-16-20241201","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/j.jhep.2007.07.022","article-title":"The clinical significance of persistently normal ALT in chronic hepatitis B infection.","volume":"47","author":"Lai","year":"2007","journal-title":"J Hepatol"},{"key":"R31-16-20241201","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1053\/j.gastro.2008.02.075","article-title":"Virologic and histologic features of chronic hepatitis B virusinfected asymptomatic patients with persistently normal ALT.","volume":"134","author":"Kumar","year":"2008","journal-title":"Gastroenterology"},{"key":"R32-16-20241201","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/j.cgh.2007.01.005","article-title":"Chronic hepatitis B virus carriers in the immunotolerant phase of infection: histologic findings and outcome.","volume":"5","author":"Andreani","year":"2007","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R33-16-20241201","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1002\/hep.21724","article-title":"Natural history and disease progression in Chinese chronic hepatitis B patients in immunetolerant phase.","volume":"46","author":"Hui","year":"2007","journal-title":"HEPATOLOGY"},{"key":"R34-16-20241201","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1136\/bmj.38050.593634.63","article-title":"Normal serum aminotransferase concentration and risk of mortality from liver diseases: prospective cohort study.","volume":"328","author":"Kim","year":"2004","journal-title":"BMJ"},{"key":"R35-16-20241201","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1136\/gut.2005.065136","article-title":"Prognostic determinants for chronic hepatitis B in Asians: therapeutic implications.","volume":"54","author":"Yuen","year":"2005","journal-title":"Gut"},{"key":"R36-16-20241201","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1053\/j.gastro.2004.06.021","article-title":"Natural history of chronic HBV carriers in northern Italy: morbidity and mortality after 30 years.","volume":"127","author":"Manno","year":"2004","journal-title":"Gastroenterology"},{"key":"R37-16-20241201","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1136\/gut.2007.128496","article-title":"Longterm outcome of chronic hepatitis B in Caucasian patients: mortality after 25 years.","volume":"57","author":"Fattovich","year":"2008","journal-title":"Gut"},{"key":"R38-16-20241201","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1053\/jhep.2002.33638","article-title":"Longterm outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis B.","volume":"35","author":"Hsu","year":"2002","journal-title":"HEPATOLOGY"},{"key":"R39-16-20241201","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1002\/hep.22476","article-title":"Treatment recommendations for chronic hepatitis B: an evaluation of current guidelines based on a natural history study in the United States.","volume":"48","author":"Tong","year":"2008","journal-title":"HEPATOLOGY"},{"key":"R40-16-20241201","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1001\/jama.300.5.555","article-title":"Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS SocietyUSA panel.","volume":"300","author":"Hammer","year":"2008","journal-title":"JAMA"},{"issue":"RR","key":"R42-16-20241201","first-page":"1","article-title":"MMWR Recomm R","volume":"40","year":"1991","journal-title":"ep"},{"key":"R43-16-20241201","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/S1386-6532(03)00087-8","article-title":"Hepatitis B virus (HBV) and hepatitis C virus (HCV) infections in health care workers (HCWs): guidelines for prevention of transmission of HBV and HCV from HCW to patients.","volume":"27","author":"Gunson","year":"2003","journal-title":"J Clin Virol"},{"key":"R44-16-20241201","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1111\/j.1365-2893.2006.00809.x","article-title":"Prolonged antiviral therapy for hepatitis B virusinfected health care workers: a feasible option to prevent work restriction without jeopardizing patient safety.","volume":"14","author":"Buster","year":"2007","journal-title":"J Viral Hepat"}],"container-title":["Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fhep.22931","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.lww.com\/01515467-200905001-00016","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T13:10:47Z","timestamp":1733058647000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/01515467-200905001-00016"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,5]]},"references-count":43,"journal-issue":{"issue":"Suppl. 5","published-print":{"date-parts":[[2009]]}},"URL":"https:\/\/doi.org\/10.1002\/hep.22931","relation":{},"ISSN":["0270-9139"],"issn-type":[{"value":"0270-9139","type":"print"}],"subject":[],"published":{"date-parts":[[2009,5]]}}}